1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Groleau A, Côté J. Comparison between two premedication regimens of dexamethasone before a pemetrexed-based chemotherapy: a single-center experience study. J Oncol Pharm Pract . 2020;26(3):612-618. https://doi.org/10.1177/1078155219862040
3Rusthoven JJ, Eisenhauer E, Butts C, et al; National Cancer Institute of Canada Clinical Trials Group. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non–small-cell lung cancer: a phase II study. J Clin Oncol. 1999;17(4):1194-1199. http://dx.doi.org/10.1200/jco.1999.17.4.1194
4Usui N, Kondo Y, Okamoto N, et al. Evaluation of the preventive effect of dexamethasone for rash in patients treated with pemetrexed. Ann Oncol. 2014;25(suppl 5):v55. Japanese Society of Medical Oncology abstract O1-20-5. https://doi.org/10.1093/annonc/mdu435.49
5Sakurada T, Kakiuchi S, Tajima S, et al. Pemetrexed-induced rash may be prevented by supplementary corticosteroids. Biol Pharm Bull. 2015;38(11):1752-1756. https://doi.org/10.1248/bpb.b15-00435
6Elsoueidi R, Lander MJ, Richa EM, Adane ED. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions. J Oncol Pharm Pract. 2016;22(2):271-274. https://doi.org/10.1177/1078155215583523
7Usui N, Kondo Y, Ryota N, et al. Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash. Eur J Hosp Pharm. 2017;24(5):283-285. https://doi.org/10.1136/ejhpharm-2016-000957
8Clark SK, Anselmo LM. Incidence of cutaneous reactions with pemetrexed: comparison of patients who received three days of oral dexamethasone twice daily to patients who did not. J Oncol Pharm Pract. 2019;25(7):1645-1650. https://doi.org/10.1177/1078155218804869
9Sakurada T, Nokihara H, Koga T, et al. Prevention of pemetrexed-induced rash using low-dose corticosteroids: a phase II study. Oncologist. 2022;27(7):e554-e560. https://doi.org/10.1093/oncolo/oyab077